IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance
This study has suspended participant recruitment.
(Study is currently on hold and recruitment may resume in the future)
Sponsor:
University Health Network, Toronto
Collaborator:
The Prostate Cancer Research Foundation of Canada
Information provided by (Responsible Party):
University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT00744549
First received: August 29, 2008
Last updated: July 14, 2015
Last verified: July 2015
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether antioxidants (vitamin E, selenium and lycopene)can change(reduce)prostate tumor size or blood flow to the prostate as determined by MRI imaging among men on Active Surveillance.
| Condition | Intervention | Phase |
|---|---|---|
| Cancer of the Prostate Prostate Cancer Prostatic Neoplasms | Dietary Supplement: Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E Drug: Placebo | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double Blind (Participant, Investigator) Primary Purpose: Treatment |
| Official Title: | The Impact of Antioxidants on MRI Markers of Cell Proliferation and Hypoxia Among Men on Active Surveillance With Early Stage Prostate Cancer |
Resource links provided by NLM:
Genetics Home Reference related topics:
prostate cancer
Drug Information available for:
Lycopene
U.S. FDA Resources
Further study details as provided by University Health Network, Toronto:
Primary Outcome Measures:
- To determine the impact of combination vitamin E, lycopene, and selenium on MRI detected prostate tumor size and/or tumor blood flow among me on active surveillance [ Time Frame: At baseline MRI compared to 1-year MRI compared to 2-year MRI ]
| Estimated Enrollment: | 40 |
| Study Start Date: | May 2008 |
| Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: A
This group of men will be on active treatment (antioxidants) for one year and placebo for the second year.
|
Dietary Supplement: Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E
Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU
Drug: Placebo
Twice a day with meals.
|
|
Experimental: B
This group of men will be on placebo for one year and active treatment (antioxidants) for the second year.
|
Dietary Supplement: Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E
Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU
Drug: Placebo
Twice a day with meals.
|
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- MRI detectable prostate cancer
- PSA less than 15 ng/ml
- Gleason score <= 7
- Prostate cancer staging T1c or T2a
Exclusion Criteria:
- Concurrent use of high-dose vitamins which include selenium, lycopene, vitamin D or vitamin E
- Other malignancies diagnosed or requiring treatment within the past 5 years (except superficial bladder cancer or basal cell carcinoma)
- Current use of Proscar or Avodart
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00744549
Please refer to this study by its ClinicalTrials.gov identifier: NCT00744549
Locations
| Canada, Ontario | |
| University Health Network - Princess Margaret Hospital | |
| Toronto, Ontario, Canada, M5G 2M9 | |
Sponsors and Collaborators
University Health Network, Toronto
The Prostate Cancer Research Foundation of Canada
Investigators
| Principal Investigator: | Neil Fleshner | Princess Margaret Hospital, Canada |
More Information
| Responsible Party: | University Health Network, Toronto |
| ClinicalTrials.gov Identifier: | NCT00744549 History of Changes |
| Other Study ID Numbers: |
07-0580-B |
| Study First Received: | August 29, 2008 |
| Last Updated: | July 14, 2015 |
Keywords provided by University Health Network, Toronto:
|
Male Urogenital Diseases Antioxidants Vitamin E |
Vitamin D Lycopene Selenium |
Additional relevant MeSH terms:
|
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Genital Diseases, Male Prostatic Diseases Vitamins Vitamin D Ergocalciferols Vitamin E Tocopherols Tocotrienols alpha-Tocopherol |
Cholecalciferol Selenium Antioxidants Lycopene Micronutrients Growth Substances Physiological Effects of Drugs Bone Density Conservation Agents Molecular Mechanisms of Pharmacological Action Protective Agents Trace Elements Radiation-Protective Agents Anticarcinogenic Agents Antineoplastic Agents |
ClinicalTrials.gov processed this record on June 23, 2017